Patents by Inventor Gregory HUSSACK

Gregory HUSSACK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serum albumin binding antibodies for tuneable half-life extension of biologics
    Patent number: 11384141
    Abstract: The present document describes an antibody or an antigen-binding fragment that bind to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), for half-life extension of biologics. The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of removing molecules from serum.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: July 12, 2022
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Gregory Hussack, Jamshid Tanha, Kevin Henry, Traian Sulea
  • BLOOD-BRAIN BARRIER TRANSMIGRATING THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20210253715
    Abstract: The present invention relates to a compound comprising an antibody or a fragment thereof operable to transmigrate across the blood-brain barrier (BBB), and a polypeptide related to the treatment of lysosomal storage disease (LSD), for the treatment of ?-synucleinopathies, or both. The present invention also relates to pharmaceutical compositions and methods for 5 treating LSDs, treating, ?-synucleinopathies, or both.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 19, 2021
    Inventors: Hung FANG, Danica STANIMIROVIC, Arsalan HAQQANI, Will COSTAIN, Gregory HUSSACK
  • SERUM ALBUMIN BINDING ANTIBODIES FOR TUNEABLE HALF-LIFE EXTENSION OF BIOLOGICS
    Publication number: 20210253679
    Abstract: The present document describes an antibody or an antigen-binding fragment that bind to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), for half-life extension of biologics. The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of removing molecules from serum.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 19, 2021
    Inventors: Gregory HUSSACK, Jamshid TANHA, Kevin HENRY, Traian SULEA
  • CLOSTRIDIUM DIFFICILE-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20210171613
    Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for TcdA. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.
    Type: Application
    Filed: July 9, 2018
    Publication date: June 10, 2021
    Applicant: National Research Council of Canada
    Inventors: Traian SULEA, Gregory HUSSACK, Jamshid TANHA, Enrico O. PURISIMA